Recombinant Human Erythropoietin for the Treatment of Renal Anaemia in Children
- 71 Downloads
Background: Drug doses for children are usually calculated by reducing adult doses in proportion to bodyweight. The clinically effective dose of recombinant human erythropoietin (epoetin) in children, however, seems to be higher than predicted by this calculation.
Objective: To determine the quantitative relationship between epoetin dose, bodyweight and response in children with end-stage renal disease.
Patients and Methods: The time-course of haemoglobin in 52 children during long-term treatment with epoetin beta was analysed by population pharmacodynamic modelling. Patients were 5–20 years old and weighed 16–53kg at the beginning of treatment. Epoetin beta was given intravenously three times per week after haemodialysis. Doses ranged from 110 to 7500IU (3–205 IU/kg). Haemoglobin versus time was described by assuming that the haemoglobin level rises after each dose due to the formation of new red blood cells, which then survive according to a logistic function. The initial rise after each dose was modelled in terms of absolute dose (not dose/kg). A parametric analysis was done with NONMEM, followed by a nonparametric analysis with NPAG.
Results: Dose-response was best described by a sigmoid maximum-effect (Emax) model with median Emax = 0.29 g/dL, median 50% effective dose (ED50) = 2400IU and shape parameter γ = 2. The estimated median survival time of the epoetin-induced red blood cells, τ, was 76 days. Neither of the dose-response parameters Emax and ED50 showed dependence on bodyweight. The median haemoglobin response to a standard dose, 0.042 g/dL for 1000IU, was similar to that reported for adults with intravenous administration.
Conclusions: Doses for children in this age range should be specified as absolute amounts rather than amounts per unit bodyweight. Initial doses can be calculated individually, based on haemoglobin level before treatment, the desired haemoglobin at steady state and the median population parameters Emax, ED50 and τ.
KeywordsRecombinant Human Erythropoietin Cystinosis Renal Anaemia Absolute Dose Constant Dose Rate
Supported by the Deutsche Forschungsgemeinschaft, grant no. PO 482/2-1. The original data were kindly made available by Roche AG, Mannheim, Germany. We are grateful to Karl Schaerer and Sunny Hong Chapel for stimulating discussions. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.
- 1.Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 Suppl. 5: 1–50Google Scholar
- 2.National Kidney Foundation. K/DOQI Clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 2001; 37Suppl. 1: S182–238Google Scholar
- 3.Eckardt KU. Erythropoietin: Karriere eines Hormons. Dtsch Arztebl 1998; 95: A255–90Google Scholar
- 4.Scigalla P. Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with endstage renal disease. In: Baldamus CA, Scigalla P, Wieczorek L, et al, editors. Erythropoietin in renal and non-renal anemias. Basel: Karger, 1991Google Scholar
- 6.Jabs K, Alexander S, McCabe D. Primary results from the U.S. multicenter pediatric recombinant erythropoietin (epo) study [abstract]. J Am Soc Nephrol 1994; 5: 456Google Scholar
- 9.Uehlinger DE, Gotch FA. A pharmacodynamic model of erythropoietin therapy for uremic anemia [abstract]. J Am Soc Nephrol 1990; 1: 324Google Scholar
- 11.Brockmoeller J, Koechling J, Weber W, et al. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in hemodialysis patients. Br J Clin Pharmacol 1992; 34: 499–508Google Scholar
- 13.Matzke GR, Comstock T, Frye RF, et al. Computerized Bayesian pharmacodynamic modeling for erythropoietin dosage individualization [abstract]. J Am Soc Nephrol 1994; 5: 464Google Scholar
- 15.Scigalla P, Bonzel KE, Bulla M, et al. Therapy of renal anemia with recombinant human erythropoietin in children with endstage renal disease. In: Gurland HL, Moran J, Samtleben W, et al, editors. Erythropoietin: from molecular structure to clinical application. Basel: Karger, 1989Google Scholar
- 17.Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore (MD): Williams & Wilkins, 1995Google Scholar
- 18.Harris JW, Kellermeyer RW. The Red Cell. 2nd ed. Cambridge (MA): Harvard University Press, 1970Google Scholar
- 21.Beal SL, Sheiner LB, editors. NONMEM version V.1.1, user’s guides. San Francisco (CA): NONMEM Project Group, University of California, San Francisco, 1999Google Scholar
- 22.Leary RH, Jelliffe RW, Schumitzky A, et al. Non-parametric pharmacokinetic/dynamic population modeling with adaptive grids [abstract]. Clin Pharmacol Ther 2001; 69: P58Google Scholar
- 23.MathSoft Inc. S-Plus, version 6.0, release 1 for Linux 2.2.12 or higher. Seattle (WA): MathSoft Inc., 2001Google Scholar
- 38.Steimer JL, Mallet A, Mentre F. Estimating interindividual pharmacokinetic variability. In: Rowland M, Sheiner LB, Steimer JL, editors. Variability in drug therapy. New York: Raven Press, 1985: 65–111Google Scholar